Inactive Instrument

Prometheus Biosciences, Inc.

Equities

RXDX

US74349U1088

Biotechnology & Medical Research

Merck in late-stage talks to acquire Prometheus Biosciences -WSJ

April 16, 2023 at 12:24 am

(Reuters) - Merck & Co is in late-stage talks to acquire Prometheus Biosciences Inc to get its hands on promising immune disease treatments, the Wall Street Journal reported on Sunday citing people familiar with the matter.

(Reporting by Kanjyik Ghosh in Bengaluru; Editing by Tom Hogue)

Latest news about Prometheus Biosciences, Inc.

S&P 500 Posts Weekly Decline Led by Real Estate, Energy as Fed Officials Point to More Rate Increases	23-06-23	MT
Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from S&P Global BMI Index	23-06-21	CI
Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from S&P TMI Index	23-06-21	CI
Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from S&P Biotechnology Select Industry Index	23-06-21	CI
Global markets live: Adobe, Eli Lilly, Nasdaq, Intel, UBS...	23-06-20
Paris-listed Drugmaker Merck & Co. Buys Prometheus Biosciences	23-06-19	MT
Prometheus Biosciences, Inc.(NasdaqGM:) dropped from NASDAQ Composite Index	23-06-19	CI
Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from NASDAQ Biotechnology Index	23-06-19	CI
Merck & Company Completes Acquisition of Prometheus Biosciences for $10.8 Billion in Cash; to Cut EPS Outlook in August	23-06-16	MT
Prometheus Biosciences, Inc. Announces Management Changes	23-06-16	CI
Prometheus Biosciences, Inc. Announces Cessation of Mark C. McKenna as CEO	23-06-16	CI
Prometheus Biosciences, Inc. Announces Cessation of Keith W. Marshall as CFO	23-06-16	CI
Merck & Co., Inc. completed the acquisition of Prometheus Biosciences, Inc. from a group of shareholders.	23-06-15	CI
Analysis-Amgen's antitrust woes spur wider pharmaceutical deal fears	23-05-17	RE
US FTC sues to block Amgen's $27.8 bln deal for Horizon Therapeutics	23-05-16	RE
North American Morning Briefing : Stock Futures -3-	23-05-11	DJ
Jefferies Downgrades Prometheus Biosciences to Hold From Buy, Adjusts Price Target to $200 From $160	23-05-10	MT
Prometheus Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Earnings Flash (RXDX) PROMETHEUS BIOSCIENCES Reports Q1 Revenue $1.1M	23-05-09	MT
Merck & Co. Files Six-Part Shelf Offering of Unsecured Senior Debt Obligation Notes	23-05-08	MT
Drugmakers scout for deals, ramp up research spending	23-04-27	RE
North American Morning Briefing : Sentiment -3-	23-04-19	DJ
Global markets live: EasyJet, Bank of America, Goldman Sachs, J&J, Alphabet...	23-04-18
Credit Suisse Downgrades Prometheus Biosciences to Neutral From Outperform on Heels of Announced Sale to Merck & Co., Raises Price Target to $200 From $139	23-04-18	MT
RBC Downgrades Prometheus Biosciences to Sector Perform From Outperform, Lifts Price Target to $200 From $140 on Merck Deal; Speculative Risk Kept	23-04-18	MT

Chart Prometheus Biosciences, Inc.

Duration

Period

More charts

Company Profile

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company. The Company discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+48.67%	56.69B
IQVIA HOLDINGS INC.	-2.76%	41B
LONZA GROUP AG	+38.25%	38.11B
CELLTRION, INC.	-11.22%	26.89B
ICON PUBLIC LIMITED COMPANY	+9.25%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-23.10%	18.59B
BIO-TECHNE CORPORATION	+1.88%	12.39B
MEDPACE HOLDINGS, INC.	+26.43%	11.99B
UNITED THERAPEUTICS CORPORATION	+21.74%	11.88B

Other Biotechnology & Medical Research